People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Biotech / Pharma, Other Health Care, Biotechnology, Other Technology, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Greenlight Biosciences Inc. | — | Biotech / Pharma | Series D+ | $179.4M | $3.9B | 2020 |
| Genomedx Inc. | — | Other Health Care | Series B | $72.9M | $176.3M | 2016 |
| Apervita, Inc. | — | Other Health Care | Series B | $68.0M | $499.7M | 2017 |
| Integrated Diagnostics, Inc. | — | Biotechnology | Series B | $45.3M | $242.1M | 2014 |
| Palyon Medical Corp | — | Biotechnology | Series B | $45.0M | $952.5M | 2009 |
| JumpCode Genomics, Inc. | — | Biotechnology | Series B | $38.7M | $23.4M | 2020 |
| AIC Innovations Group, Inc. | — | Other Technology | Series B | $28.7M | $510.9M | 2017 |
| Amphora Medical, Inc. | — | Healthtech | Series A | $23.8M | $248.6M | 2013 |
| Insightra Medical, Inc. | — | Other Health Care | Series A | $20.0M | $100.9M | 2014 |
Michael Liang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Michael Liang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Omstead | 2 | 4 |
| CRAIG JOHNSON | 1 | 16 |
| Robert Weisskoff | 1 | 12 |
| Matthew Walker | 1 | 11 |
| Arnold Oronsky | 1 | 10 |
| Amit Shah | 1 | 10 |
| Jonathan Fleming | 1 | 9 |
| Eugene Chen | 1 | 9 |
| Stephen Davis | 1 | 8 |
| Keith Brown | 1 | 8 |
| Jason Dinges | 1 | 8 |
| Vijay Lathi | 1 | 8 |
| Jeff Anderson | 1 | 8 |
| David Furneaux | 1 | 8 |
| David Barker | 1 | 7 |
| Adam Koopersmith | 1 | 7 |
| Ganesh Kishore | 1 | 7 |
| Court Turner | 1 | 6 |
| Andrey Zarur | 1 | 6 |
| Eric O'Brien | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.